Ranbaxy Launches Flotral for Urological Disorder Amongst Ageing Males

Main Category: Urology / Nephrology
Article Date: 22 Nov 2004 - 12:00 PDT

email to a friend   printer friendly   opinions  

Safe And Convenient Treatment for Benign Prostatic Hyperplasia - Ranbaxy Laboratories Limited (Ranbaxy) announced the launch of its Benign Prostatic Hyperplasia (BPH) formulation, branded Flotral (Alfuzosin). The drug, Alfuzosin, is being introduced for the first time in India. Flotral 10 mg is a new Uro-selective alpha1-blocker, prescription medicine that provides effective relief from signs and symptoms of BPH, a urological disorder. Flotral, a once a day medication, has been developed using the NDDS (Novel Drug Delivery System) technology platform, resulting in better patient compliance.

BPH, is caused due to the enlargement of the prostate gland and commonly afflicts the ageing male population. Over 50 percent of men above the age of 60 and around 80 percent beyond the age of 80, suffer from BPH in India and around the world. If left untreated, BPH can lead to serious health problems, including urinary tract infections, bladder and kidney damage, bladder stones and inability to hold urine.

Flotral (Alfuzosin) is a new, convenient and safe formulation. Extensive clinical studies demonstrate that Alfuzosin is highly selective resulting in a low incidence of side effects such as postural hypotension and syncope. Alfuzosin also has a low risk of sexual side effects whereas Erectile Dysfunction and Ejaculatory disorders are well-recognized side effects of other alpha-blockers.

Commenting on the launch of Flotral, Dr Ganesh Gopalkrishnan, Head of Department, Urology, Christian Medical College (CMC), Vellore, India, said, "Flotral (Alfuzosin) will provide Indian doctors with an efficacious uro-selective alpha1 blocker for patients with LUTS (Lower Urinary Tract Symptoms). Alfuzosin has been shown in clinical trials to result in a significant decrease in post-void residual urine volume, a known risk factor for AUR (Acute Urinary Retention)."

"The launch of Flotral further expands Ranbaxy's key strategic product portfolio and establishes the Company's commitment to build its Urology franchise through its competitive edge technology of NDDS", said, Mr. Sanjeev I. Dani, Regional Director- India, Ranbaxy.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries.
http://www.ranbaxy.com/newsroom

• Additional
• References
• Citations